Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Sarepta Therapeutics, Inc. (SRPT) had Normalized Pre-Tax Income of $-407.68M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$442.93M |
|
$-412.23M |
|
$398.71M |
|
$44.23M |
|
$854.52M |
|
$-411.58M |
|
$3.91M |
|
$-407.68M |
|
|
Normalized Pre-Tax Income |
$-407.68M |
$-412.23M |
|
$-412.23M |
|
$-412.23M |
|
$-412.23M |
|
$-411.58M |
|
-- |
|
104.79M |
|
104.79M |
|
$-3.93 |
|
$-3.93 |
|
| Balance Sheet Financials | |
$2.54B |
|
$345.12M |
|
$811.76M |
|
$3.35B |
|
$1.10B |
|
$828.97M |
|
$1.11B |
|
$2.21B |
|
$1.14B |
|
$1.14B |
|
$1.14B |
|
104.96M |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|